PBT up 58% on continuing ops, but operating cash flow fell 22%

That changes the read on the headline comparison: reported revenue of $249.0m is continuing-operations only and is 2.0% below the $254.0m prior total, but on a like-for-like continuing basis (excluding $18.4m of prior-year automation revenue) the underlying business grew 3.4% from $240.9m.

Profit before tax from continuing operations rose 58.2% to $31.0m, but NPAT grew only 30.9% to $22.9m because the effective tax rate normalised from 10.6% to 23.9%. Operating cash flow fell 22.2% to $40.5m while capex rose 148.9% to $15.5m, taking cash conversion sharply lower even as the balance sheet finished with no debt (vs $1.6m prior) and $18.8m of cash.

• PBT growth of 58.2% on 3.4% continuing-revenue growth was driven by margin expansion in the higher-mix segments: herd testing result rose to $20.1m on revenue of $35.4m (gross margin 56.8% from 33.7%), and farm software result rose to $36.6m on revenue of $50.8m (gross margin 72.1% from 62.4%). This matters because mix is shifting toward higher-margin, less cyclical revenue streams.
• Tax distortion suppresses the NPAT signal. The +27.3 percentage-point gap between PBT and NPAT growth is almost entirely a tax-rate effect. PBT growth is the cleaner read on operating performance; users anchoring to the 30.9% NPAT figure will understate underlying earnings improvement.
• Cash conversion deteriorated even as profit rose. OCF fell $11.6m while PBT rose $11.4m, and capex more than doubled to $15.5m (6.2% of revenue, up from a net inflow on disposals last year). FCF pre-lease of $25.0m covered the $17.8m dividend (FCF payout 71.3%), but the prior year's exceptional $58.2m of FCF and 103.5% NPAT payout are not a useful baseline.

The relevant questions are durability rather than pacing: whether the herd testing and farm software margin step-ups are sustainable, whether the elevated capex run-rate (split roughly evenly between software development and physical assets) becomes recurring, and whether the tax rate stays near 23.9%. The 78.2% NPAT payout looks more sustainable than the 103.5% prior payout, but the lower dividend per share (12.51c vs 12.75c) signals the board is calibrating to a more normalised earnings and cash base rather than the prior year's tax-assisted print.

PBT growth comes from the core continuing segments, with herd testing and farm software both expanding margin meaningfully and NZ market genetics holding share at 39.9% of revenue. The disposal of farm automation removes a low-margin business (27.4% gross margin last year on $18.4m revenue) and should be earnings-accretive on mix.

The cash quality is the weaker side of the print. OCF fell 22.2% against rising profit, which means working capital and timing absorbed cash even before the capex step-up. Receivable days extended to 63.0 from 59.2, partly offsetting an inventory release. The 148.9% capex increase ($7.7m software development plus $7.8m of land, buildings and equipment) is investment rather than deterioration, but it materially lowered FCF-to-NPAT to 108.8% from an unusually high 333% prior. Investors should treat the prior-year FCF and payout ratios as the anomaly, not the current year.

This briefing cannot assess management's forward outlook, segment guidance, or capital-return policy beyond what is disclosed in the supplied release.